IB Acquisition Corp. (IBAC): Total Liabilities
$1.83M
As of 2025-09-30
$2.45M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $1.83M | +153.7% | 2025-12-29, Balance as of period end |
| 2024-09-30 | $722.2K | n/m | 2025-12-29, Balance as of period end |
| 2023-09-30 | $58.0K | n/a | 2024-12-26, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| IB Acquisition Corp. (IBAC) | 2025-09-30 | $1.83M | +153.7% |
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | $3.68M | -5.8% |
| iSpecimen Inc. (ISPC) | 2025-12-31 | $6.44M | +6.7% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $33.50M | -8.1% |
| NRC Health (NRC) | 2025-12-31 | $120.89M | +19.4% |
| OneMedNet Corp (ONMD) | 2025-12-31 | $5.12M | -74.0% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $31.02M | -6.6% |
| Absci Corp (ABSI) | 2025-12-31 | $26.85M | -22.1% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $33.89M | -10.7% |
Compare IBAC, BIAF, ISPC, FOXO side by side · Screen every company in Services-Commercial Physical & Biological Research ↗